230 related articles for article (PubMed ID: 34607517)
21. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M
Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025
[TBL] [Abstract][Full Text] [Related]
22. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP; Konopleva M; Pemmaraju N
Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
[TBL] [Abstract][Full Text] [Related]
23. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
[TBL] [Abstract][Full Text] [Related]
24. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
[TBL] [Abstract][Full Text] [Related]
25. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
[No Abstract] [Full Text] [Related]
27. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
Gulati R; Abu-Salah A; Salous T; Nassiri M
J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
[TBL] [Abstract][Full Text] [Related]
28. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
Bôle-Richard E; Fredon M; Biichlé S; Anna F; Certoux JM; Renosi F; Tsé F; Molimard C; Valmary-Degano S; Jenvrin A; Warda W; Pallandre JR; Bonnefoy F; Poussard M; Deschamps M; Petrella T; Roumier C; Macintyre E; Féger F; Brissot E; Mohty M; HoWangYin KY; Langlade-Demoyen P; Loustau M; Caumartin J; Godet Y; Binda D; Pagadoy M; Deconinck E; Daguindau E; Saas P; Ferrand C; Angelot-Delettre F; Adotévi O; Garnache-Ottou F
Leukemia; 2020 Dec; 34(12):3228-3241. PubMed ID: 32111969
[TBL] [Abstract][Full Text] [Related]
29. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
[TBL] [Abstract][Full Text] [Related]
30. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
Wu SJ; Sadigh S; Lane AA; Pinkus GS
Am J Clin Pathol; 2023 May; 159(5):455-463. PubMed ID: 36880313
[TBL] [Abstract][Full Text] [Related]
31. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
32. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
[TBL] [Abstract][Full Text] [Related]
35. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
36. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kerr D; Zhang L; Sokol L
Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
[TBL] [Abstract][Full Text] [Related]
37. Plasmacytoid dendritic cell neoplasms.
Lee YJ; Kim Y; Park SH; Jo JC
Blood Res; 2023 Apr; 58(S1):90-95. PubMed ID: 37105563
[TBL] [Abstract][Full Text] [Related]
38. CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.
Testa U; Pelosi E; Castelli G
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547472
[TBL] [Abstract][Full Text] [Related]
39. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
Kerr D; Sokol L
Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
[TBL] [Abstract][Full Text] [Related]
40. CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
Pelosi E; Castelli G; Testa U
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]